Resectability and neoadjuvant chemoimmunotherapy in stage II–III non-small cell lung cancer: a European case-vignette survey
Clicks: 1
ID: 320004
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #57 of 79 articles by views in Interdisciplinary CardioVascular and Thoracic Surgery
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: Immunotherapy has expanded curative-intent options in non-small cell lung cancer (NSCLC), but management recommendations remain variable. This survey examined variation in resectability assessment and treatment sequencing among thoracic oncology clinicians managing stage II-III NSCLC. METHODS: A web-based case-vignette survey was distributed to thoracic oncology clinicians, primarily in Europe. Seven stage II-III NSCLC vignettes, based on the ninth-edition TNM classification, were presented. Treatment options were recorded as independent yes/no endorsements. The primary outcome was endorsement of neoadjuvant chemoimmunotherapy among vignette evaluations considered resectable. Vignette-level binary outcomes were analysed using exploratory generalised estimating equations clustered by respondent. RESULTS: Sixty-eight respondents provided vignette-level assessments. Resectability was generally endorsed in the N0/N1 and selected single-station N2 scenarios but was substantially lower in the multi-station and T3/T4 N2 scenarios. Among cases considered resectable, endorsement of neoadjuvant chemoimmunotherapy increased markedly in N2 scenarios, whereas cases considered unresectable were commonly associated with endorsement of concurrent chemoradiotherapy. In an exploratory model restricted to resectable-branch evaluations (249 observations from 57 respondents), any N2 involvement was associated with endorsement of neoadjuvant chemoimmunotherapy (adjusted odds ratio 28.42, 95% confidence interval 7.31-110.42; P < 0.001), though the wide interval reflects the limited effective sample. CONCLUSIONS: Variation was greatest in borderline N2 disease, particularly multi-station and higher-T N2 scenarios, where clinicians diverged in defining resectability and in selecting surgery-based versus chemoradiotherapy-based pathways. These findings support the need for clearer multidisciplinary frameworks in stage II-III NSCLC, within the limits of a surgeon-weighted respondent pool and an anatomically focused vignette set.
| Reference Key |
openalex_W7167571966
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Savvas Lampridis, Akshay J Patel, E. Josephides, Fabian Doerr, Carmelina Cristina Zirafa, Seray Hazer, Andrés Obeso, Ilies Bouabdallah, M A Casiraghi, Andrea Billè |
| Journal | Interdisciplinary CardioVascular and Thoracic Surgery |
| Year | 2026 |
| DOI |
10.1093/icvts/ivag196
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.